Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Cell Death & Disease
|
January 16, 2015
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G S Choudhary, S Al-Harbi, S Mazumder, et al.
Cell Death & Disease
|
July 24, 2024
Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G S Choudhary, S Al-Harbi, S Mazumder, et al.
American Journal of Clinical Pathology
|
November 17, 2001
Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically
J L Frater, K F McCarron, J P Hammel, et al.
Leukemia
|
March 25, 2015
Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma
D Pore, J Bodo, A Danda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2010
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
K A Blum, S-H Jung, J L Johnson, et al.
Bone Marrow Transplantation
|
May 29, 2007
Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
S D Smith, B J Bolwell, L A Rybicki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)
P Martin, S-H Jung, B Pitcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2009
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
J W Sweetenham, B Goldman, M L LeBlanc, et al.
Leukemia
|
May 15, 2009
Monoclonal antibodies against IREM-1: potential for targeted therapy of AML
W Korver, X Zhao, S Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 1999
Mechanisms of apoptosis in T cells from patients with renal cell carcinoma
R G Uzzo, P Rayman, V Kolenko, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Cell Death & Disease
|
January 16, 2015
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G S Choudhary, S Al-Harbi, S Mazumder, et al.
Cell Death & Disease
|
July 24, 2024
Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G S Choudhary, S Al-Harbi, S Mazumder, et al.
American Journal of Clinical Pathology
|
November 17, 2001
Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically
J L Frater, K F McCarron, J P Hammel, et al.
Leukemia
|
March 25, 2015
Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma
D Pore, J Bodo, A Danda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2010
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
K A Blum, S-H Jung, J L Johnson, et al.
Bone Marrow Transplantation
|
May 29, 2007
Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
S D Smith, B J Bolwell, L A Rybicki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)
P Martin, S-H Jung, B Pitcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2009
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
J W Sweetenham, B Goldman, M L LeBlanc, et al.
Leukemia
|
May 15, 2009
Monoclonal antibodies against IREM-1: potential for targeted therapy of AML
W Korver, X Zhao, S Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 1999
Mechanisms of apoptosis in T cells from patients with renal cell carcinoma
R G Uzzo, P Rayman, V Kolenko, et al.
Page
of 8